Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | CSF3R | Q99062 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206114 | 0.99 | HDAC1 (0.46) | HDAC1HDAC6PPARAPPARGCNR1 | |
| SCHEMBL26205853 | 0.96 | HDAC1 (0.42) | HDAC1HDAC6PPARAPPARGMTNR1A | |
| SCHEMBL26206374 | 0.89 | PPARA (0.51) | HDAC1HDAC6PPARAPPARGCNR1 | |
| SCHEMBL26205650 | 0.85 | SLC7A5 (0.46) | MTNR1AMTNR1B | |
| SCHEMBL22526755 | 0.84 | PPARA (0.42) | HDAC1HDAC6PPARAPPARGCNR1 | |
| SCHEMBL26206366 | 0.84 | PPARA (0.47) | HDAC1HDAC6PPARAPPARGCSF3R | |
| SCHEMBL26206104 | 0.84 | F2 (0.38) | CNR1CNR2 | |
| SCHEMBL22526876 | 0.82 | HDAC1 (0.41) | HDAC1HDAC6PPARAPPARGCNR1 | |
| SCHEMBL26206096 | 0.81 | MEN1 (0.38) | PPARAPPARGCNR2MTNR1A | |
| SCHEMBL26206102 | 0.81 | MAPT (0.39) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | HDAC1 930/4885HDAC6 181/4885PPARA 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.